drugset / Trial / NCT01018069
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
RandomizedParallel-groupOpen-labelTreatment
Summary
To determine if AEG35156 can enhance the combined complete remission (CR) and CR with incomplete platelet recovery (CRp) rate of high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine based frontline induction regimen.
Timeline
- Start
- 2009-11
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | AEG35156 | Antisense oligonucleotide | 650 mg | Other |
| Comparator | Cytarabine | Small molecule | 1.5 g | Other |
| Comparator | Idarubicin | Small molecule | 12 mg/m2 | Other |